Paclitaxel/5-FU Promising in Metastatic Breast Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

ROME, Italy-The combination of paclitaxel (Taxol), fluorouracil (5-FU), and leucovorin, with G-CSF support, in pretreated patients with advanced breast cancer had a good toxicity profile and an encouraging response rate in a study from the Regina Elena Cancer Institute, Rome.

ROME, Italy—The combination of paclitaxel (Taxol), fluorouracil (5-FU),and leucovorin, with G-CSF support, in pretreated patients with advancedbreast cancer had a good toxicity profile and an encouraging response ratein a study from the Regina Elena Cancer Institute, Rome.

In the poster presentation, Dr. E. Terzoli described 16 heavily pretreatedadvanced breast cancer patients who received paclitaxel, 135 to 175 mg/m²onday 1 and fluorouracil, 350 to 375 mg/m², plus leucovorin, 10 to 100mg/m², on days 1 to 3. The cycle was repeated every three weeks withG-CSF added to prevent neutropenia.

The combination therapy was delivered as first-line metastatic treatmentin three patients, second-line in five patients, and third-line or higherin eight patients. All patients had received previous anthracyclines, andeight had taken hormones.

Five of 10 evaluable patients had a partial response, and in four ofthese patients, the treatment represented third-line chemotherapy. Overall,the combination was well tolerated.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content